Search research articles
Contact Us
Filters
Showing results (131-140 of 144) with videos related to
Page
of 15
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 6, 2016
Scoring System Prognostic of Outcome in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome
Brian C Shaffer, Kwang Woo Ahn, Zhen-Huan Hu, et al.
Blood
|
August 1, 2025
Sequential Targeting in Multiple Myeloma: Talquetamab, a GPRC5D bispecific antibody, as a Bridge to BCMA CAR-T cell therapy
Binod Dhakal, Othman Salim Akhtar, David Fandrei, et al.
Bone Marrow Transplantation
|
February 1, 2018
Donor body mass index does not predict graft versus host disease following hematopoietic cell transplantation
Lucie M Turcotte, Tao Wang, Michael T Hemmer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 7, 2025
Erratum: Comparison of Standard-of-Care Idecabtagene Vicleucel and Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma
Doris K Hansen, Lauren C Peres, Danai Dima, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 18, 2025
Comparison of Standard-of-Care Idecabtagene Vicleucel and Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma
Doris K Hansen, Lauren C Peres, Danai Dima, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
November 1, 2019
Maintenance Tyrosine Kinase Inhibitors Following Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Myelogenous Leukemia: A Center for International Blood and Marrow Transplant Research Study
Zachariah DeFilipp, Richard Ancheta, Ying Liu, et al.
Blood Advances
|
October 6, 2025
CAR HEMATOTOX independently predicts outcomes after CD19 CAR-T therapy for acute lymphoblastic leukemia
Yannis K Valtis, Chenyu Lin, David Nemirovsky, et al.
Blood Advances
|
March 15, 2025
Universal driving restrictions beyond 4 weeks appear unnecessary following CAR-T therapy in multiple myeloma
Rahul Banerjee, Alicia Richards, Shonali Midha, et al.
Transplantation and Cellular Therapy
|
August 17, 2021
Fludarabine and Melphalan Compared with Reduced Doses of Busulfan and Fludarabine Improve Transplantation Outcomes in Older Patients with Myelodysplastic Syndromes
Betül Oran, Kwang Woo Ahn, Caitrin Fretham, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
September 2, 2015
Hematopoietic Cell Transplantation Outcomes in Monosomal Karyotype Myeloid Malignancies
Marcelo C Pasquini, Mei-Jie Zhang, Bruno C Medeiros, et al.
Page
of 15
Search research articles
Search
Showing results (131-140 of 144) with videos related to
Sort By:
Page
of 15
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 6, 2016
Scoring System Prognostic of Outcome in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome
Brian C Shaffer, Kwang Woo Ahn, Zhen-Huan Hu, et al.
Blood
|
August 1, 2025
Sequential Targeting in Multiple Myeloma: Talquetamab, a GPRC5D bispecific antibody, as a Bridge to BCMA CAR-T cell therapy
Binod Dhakal, Othman Salim Akhtar, David Fandrei, et al.
Bone Marrow Transplantation
|
February 1, 2018
Donor body mass index does not predict graft versus host disease following hematopoietic cell transplantation
Lucie M Turcotte, Tao Wang, Michael T Hemmer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 7, 2025
Erratum: Comparison of Standard-of-Care Idecabtagene Vicleucel and Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma
Doris K Hansen, Lauren C Peres, Danai Dima, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 18, 2025
Comparison of Standard-of-Care Idecabtagene Vicleucel and Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma
Doris K Hansen, Lauren C Peres, Danai Dima, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
November 1, 2019
Maintenance Tyrosine Kinase Inhibitors Following Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Myelogenous Leukemia: A Center for International Blood and Marrow Transplant Research Study
Zachariah DeFilipp, Richard Ancheta, Ying Liu, et al.
Blood Advances
|
October 6, 2025
CAR HEMATOTOX independently predicts outcomes after CD19 CAR-T therapy for acute lymphoblastic leukemia
Yannis K Valtis, Chenyu Lin, David Nemirovsky, et al.
Blood Advances
|
March 15, 2025
Universal driving restrictions beyond 4 weeks appear unnecessary following CAR-T therapy in multiple myeloma
Rahul Banerjee, Alicia Richards, Shonali Midha, et al.
Transplantation and Cellular Therapy
|
August 17, 2021
Fludarabine and Melphalan Compared with Reduced Doses of Busulfan and Fludarabine Improve Transplantation Outcomes in Older Patients with Myelodysplastic Syndromes
Betül Oran, Kwang Woo Ahn, Caitrin Fretham, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
September 2, 2015
Hematopoietic Cell Transplantation Outcomes in Monosomal Karyotype Myeloid Malignancies
Marcelo C Pasquini, Mei-Jie Zhang, Bruno C Medeiros, et al.
Page
of 15